KR101201524B1 - Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives - Google Patents
Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives Download PDFInfo
- Publication number
- KR101201524B1 KR101201524B1 KR1020100009811A KR20100009811A KR101201524B1 KR 101201524 B1 KR101201524 B1 KR 101201524B1 KR 1020100009811 A KR1020100009811 A KR 1020100009811A KR 20100009811 A KR20100009811 A KR 20100009811A KR 101201524 B1 KR101201524 B1 KR 101201524B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- formula
- scalp
- composition
- dibenzo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 210000004209 hair Anatomy 0.000 title abstract description 70
- 210000004761 scalp Anatomy 0.000 title abstract description 68
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 title abstract description 14
- 230000006872 improvement Effects 0.000 title abstract description 4
- 230000036541 health Effects 0.000 title description 9
- 230000003779 hair growth Effects 0.000 claims abstract description 21
- 201000004384 Alopecia Diseases 0.000 claims abstract description 13
- 230000003676 hair loss Effects 0.000 claims abstract description 13
- 208000024963 hair loss Diseases 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 23
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 claims description 21
- 239000002453 shampoo Substances 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000003658 preventing hair loss Effects 0.000 claims description 8
- -1 rinse Substances 0.000 claims description 8
- 230000001256 tonic effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 208000001840 Dandruff Diseases 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 32
- 206010061218 Inflammation Diseases 0.000 abstract description 24
- 208000003251 Pruritus Diseases 0.000 abstract description 23
- 230000004054 inflammatory process Effects 0.000 abstract description 22
- 230000003646 hair health Effects 0.000 abstract description 21
- 230000006378 damage Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 241000555676 Malassezia Species 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 238000011109 contamination Methods 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000003648 hair appearance Effects 0.000 abstract description 2
- 230000011506 response to oxidative stress Effects 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000523 sample Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 230000003110 anti-inflammatory effect Effects 0.000 description 15
- 230000007803 itching Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 13
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000000118 hair dye Substances 0.000 description 4
- 230000003699 hair surface Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001291477 Malassezia restricta Species 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000037389 hair physiology Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000008798 inflammatory stress Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- PFTAWBLQPZVEMU-UHFFFAOYSA-N catechin Chemical compound OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 디벤조-p-디옥신 유도체를 유효성분으로 포함하는 두피 및 모발 건강 개선용 조성물에 관한 것이다. 상기 두피 및 모발 건강 개선용 조성물은 두피 및 모발에서 발생하는 비듬균(Malassezia resista) 번식, 산화스트레스, 염증반응을 안전하면서도 효과적으로 억제함으로써 탈모예방, 모발의 생장 촉진, 비듬 방지, 두피염증 개선, 두피 가려움증 억제에 뛰어난 효과를 제공한다. 또한 본 발명의 조성물은 모발 표면의 파괴 및 미생물에 의한 오염을 효과적으로 방지함으로써 모발의 외관을 건강하고 아름답게 유지시키는 효과를 제공한다.The present invention relates to a scalp and hair health improving composition comprising a dibenzo-p-dioxin derivative as an active ingredient. The scalp and hair health improvement composition prevents hair loss, promotes hair growth, prevents dandruff, improves scalp itch by safely and effectively inhibiting the growth of malassezia (Malassezia resista), oxidative stress, and inflammatory reactions occurring in the scalp and hair. It provides an excellent effect on suppression. In addition, the composition of the present invention provides an effect of maintaining the appearance of hair healthy and beautiful by effectively preventing the destruction of the surface of the hair and contamination by microorganisms.
Description
본 발명은 두피 및 모발의 건강을 유지하고 개선시키는 디벤조-p-디옥신 유도체를 포함하는 조성물에 관한 것이다. The present invention relates to a composition comprising a dibenzo-p-dioxin derivative that maintains and improves the health of the scalp and hair.
두피 및 모발에 의해 형성되는 공간은 고온다습하여 미생물이 서식하기에 알맞은 환경을 형성한다. 적절한 위생관리 및 생활습관에 의해 건강이 유지되는 두피 및 모발 조직은 혈액순환, 대사작용, 면역작용 등의 균형을 통하여 유해균의 번식을 적절히 견제한다. 그러나 호르몬 불균형, 각종 스트레스, 위생관리 미흡 등의 요인으로 인하여 상기와 같은 균형이 깨지게 되면 두피 및 모발에 다양한 병리학적 현상이 발생할 수 있다. 예를 들어, 두피 및 모발 표면 조직에 유해균이 번창하고 염증반응이 증가하여 산화스트레스가 증가하게 되면, 두피 및 모근 주변에 조직 파괴, 혈액순환 부진, 세포생장억제, 알러지 현상 등이 나타나게 된다. 이러한 현상은 결국 탈모, 모발생장 억제, 과도한 비듬생성, 두피염증, 가려움증 등의 원인이 된다. 이러한 심각한 증상 외에도, 상기와 같은 두피 및 모발의 특수한 환경은 모발 표면을 쉽게 오염시킴으로써 모발에 의한 미적 외관을 훼손시킨다. 즉, 건강한 상태에서도 두피에서 분비되는 땀, 피지, 기타 피부 부스러기, 미생물 등에 의해 모발 표면이 오염되어 모발의 색택, 촉감 및 냄새의 질이 쉽게 저하되므로, 상기와 같은 병리학적인 조건에서 이러한 오염현상은 더욱 가속화 된다. The space formed by the scalp and hair is hot and humid to create an environment suitable for microorganisms. The scalp and hair tissues, which are maintained by proper hygiene and lifestyle, are properly restrained by the growth of harmful bacteria through a balance of blood circulation, metabolism, and immunity. However, when such balance is broken due to factors such as hormonal imbalance, various stresses, and insufficient hygiene management, various pathological phenomena may occur on the scalp and hair. For example, when harmful bacteria thrive on the scalp and hair surface tissues and inflammatory reactions increase, oxidative stress increases, tissue destruction, poor blood circulation, cell growth inhibition, and allergic symptoms appear around the scalp and hair roots. This can eventually cause hair loss, hair growth inhibition, excessive dandruff, scalp inflammation and itching. In addition to these serious symptoms, such special conditions of the scalp and hair can easily contaminate the hair surface, thereby compromising the aesthetic appearance of the hair. That is, even in a healthy state, the surface of the hair is contaminated by sweat, sebum, other skin debris, and microorganisms secreted from the scalp, so that the color of the hair, touch and smell are easily degraded. It is accelerated even more.
두피와 모발 생리작용의 항상성을 깨는 원천적인 요인들로는 호르몬 불균형, 다양한 스트레스 및 위생관리 미흡 등을 들 수 있다. 이러한 요인들은 인체와 다양한 조건으로 상호작용함으로써 두피와 모발에 복잡한 생리학적, 생화학적 불균형을 초래하며, 궁극적으로 다양한 두피 및 모발 관련 증상들을 발생시킨다. Sources that break the homeostasis of scalp and hair physiology include hormonal imbalances, various stresses, and poor hygiene. These factors interact with the human body in a variety of conditions, leading to complex physiological and biochemical imbalances in the scalp and hair, and ultimately to a variety of scalp and hair related symptoms.
한편, 현재까지 개발된 두피 및 모발 건강 개선을 추구하는 주요 제품들은 두피 및 모발 건강에 영향을 미치는 한가지 요인의 억제만을 추구함으로써 심각한 부작용을 동반하는 것으로 보고되고 있다. 예를 들어, 유전적인 요인에 의하여 남성호르몬인 DHT가 과다하여 발생하는 탈모현상을 막기 위하여 DHT 합성 효소 억제제가 개발되어 판매 되고 있으나, 부작용이 크고, 두피와 모발 생리의 항상성에 근본적인 도움을 주는데는 한계가 있다. 또한 비듬을 감소시키기 위해서 항진균제를 사용하는 제품이 출시되고 있으나, 마찬가지로 부작용의 우려가 있으며, 근본적인 모발의 건강 개선에는 한계를 나타내고 있다. 또한, 인체 안전성과 전반적인 건강을 추구한다는 관점에서 한방을 응용한 복합생약처방이 개발되고 제품화 되고 있다. 그러나, 이러한 제품은 합성성분을 사용한 제품에 비해 인체 안전성은 우수하지만, 표준화가 어렵고, 효과와 복합성분간의 상관관계를 도출하기 어렵기 때문에 효과를 극대화시키고 체계적으로 발전시키는 것에 한계가 있다. 따라서 안전성과 표준화가 용이하면서도 두피와 모발 건강을 해치는 주요 요인들을 효과적으로 제어할 수 있는 성분의 개발이 요구되고 있다. On the other hand, the main products that have been developed to improve scalp and hair health have been reported to have serious side effects by seeking only suppression of one factor affecting scalp and hair health. For example, due to genetic factors, DHT synthase inhibitors have been developed and marketed to prevent hair loss caused by excessive male hormone DHT. However, there are many side effects, and it is fundamental to help homeostasis of scalp and hair physiology. There is a limit. In addition, products that use antifungal drugs to reduce dandruff have been released, but there is a concern of side effects as well, there is a limit to fundamental hair health improvement. In addition, in view of pursuing human safety and overall health, herbal medicines have been developed and commercialized. However, these products have better human safety than products using synthetic ingredients, but are difficult to standardize and difficult to derive correlations between effects and complex ingredients. Therefore, there is a need for the development of ingredients that can easily control the major factors that damage the scalp and hair health while being safe and standardized.
본 발명은, 종래기술의 한계점을 극복하고 보다 효과적으로 두피와 모발 건강을 개선하기 위한 것으로서, 두피 및 모발의 건강유지 및 개선에 있어서 핵심적인 요소라 할 수 있는 항균, 항산화 및 항염 효과가 모두 우수하면서도, 모발과의 친화력도 우수한 성분을 포함함으로써, 낮은 농도에서도 두피 및 모발의 건강을 효과적으로 유지 개선시키며 매우 안전한, 두피 및 모발 건강 개선용 조성물을 제공하는 것을 목적으로 한다. The present invention is to overcome the limitations of the prior art and to more effectively improve the scalp and hair health, while excellent antibacterial, antioxidant and anti-inflammatory effects that can be a key factor in maintaining and improving the health of the scalp and hair. In addition, by including a component having excellent affinity with hair, it is an object to provide a composition for improving scalp and hair health, effectively maintaining and improving the health of the scalp and hair even at low concentrations.
본 발명은 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체를 유효성분으로 포함하는 두피 및 모발 건강 개선용 조성물을 제공한다.The present invention provides a composition for improving scalp and hair health comprising dibenzo-p-dioxine derivative as an active ingredient.
상기에서 디벤조-p-디옥신 유도체는 하기 화학식 1 내지 10으로 표시되는 화합물로 이루어진 군으로부터 선택되는 하나 이상의 화합물일 수 있다:The dibenzo-p-dioxin derivative may be at least one compound selected from the group consisting of compounds represented by the following Chemical Formulas 1 to 10:
[화학식1][Formula 1]
[화학식2] (2)
[화학식3][Formula 3]
[화학식4][Formula 4]
[화학식5][Formula 5]
[화학식6][Formula 6]
[화학식7][Formula 7]
[화학식8][Formula 8]
[화학식9][Chemical Formula 9]
[화학식10][Formula 10]
상기 화학식1 내지 10에서, In Chemical Formulas 1 to 10,
R은 각각 독립적으로 수소, C1~C5의 알킬, C2~C5의 알케닐, 페닐, C7~C12의 페닐알킬, C2~C20의 알카노일, C3~C20의 알케노일, 히드록시페닐, 디히드록시페닐 또는 트리하이드록시페닐이다.R is independently hydrogen, C1-C5 alkyl, C2-C5 alkenyl, phenyl, C7-C12 phenylalkyl, C2-C20 alkanoyl, C3-C20 alkenoyl, hydroxyphenyl, dihydroxy Phenyl or trihydroxyphenyl.
본 발명의 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체를 포함하는 두피 및 모발 건강 개선용 조성물은 두피 및 모발에서 발생하는 비듬균(Malassezia resista) 번식, 산화스트레스, 염증반응을 안전하면서도 효과적으로 억제함으로써 탈모예방, 모발의 생장 촉진, 비듬 방지, 두피염증 개선, 두피 가려움증 억제에 뛰어난 효과를 제공한다. 또한 본 발명의 조성물은 모발 표면의 파괴 및 미생물에 의한 오염을 효과적으로 방지함으로써 모발의 외관을 건강하고 아름답게 유지시키는 효과를 제공한다.The composition for improving scalp and hair health comprising the dibenzo-p-dioxine derivative of the present invention is safe for breeding malassezia resista, oxidative stress, and inflammatory reactions occurring in the scalp and hair. It effectively inhibits hair loss, promotes hair growth, prevents dandruff, improves scalp inflammation, and suppresses scalp itch. In addition, the composition of the present invention provides an effect of maintaining the appearance of hair healthy and beautiful by effectively preventing the destruction of the surface of the hair and contamination by microorganisms.
본 발명은 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체를 유효성분으로 포함하는 두피 및 모발 건강 개선용 조성물에 관한 것이다.
The present invention relates to a scalp and hair health improving composition comprising a dibenzo-p-dioxine derivative as an active ingredient.
본 발명자들은 두피 및 모발의 건강을 해치는 생리, 생화학적 요인인 비듬균, 염증, 산화스트레스의 작용이 서로 복합 상승작용하기 때문에 한가지 요인의 제어 만으로는 두피 및 모발 건강을 효과적이고 안전하게 개선시키기 어렵다는 개념을 인식하여, 유해균, 염증반응 및 산화스트레스의 동시적이고 효과적인 제어가 가능한 성분 또는 조성을 찾는 것을 목표로 하여 연구를 진행하였다. 또한 지속적인 사용을 통하여 발생될 수 있는 생리적 불균형을 예방할 수 있는 절대적인 안전성이 확보되는 성분 또는 조성을 찾는 것을 목표로 하였다. The present inventors recognize the concept that it is difficult to effectively and safely improve scalp and hair health only by controlling one factor because the action of physiological and biochemical factors, such as dandruff, inflammation, and oxidative stress, which harm the scalp and hair, are combined with each other. The study was conducted with the aim of finding components or compositions capable of simultaneous and effective control of harmful bacteria, inflammatory reactions and oxidative stress. It also aimed to find a component or composition that ensures absolute safety that can prevent physiological imbalances that can occur through continuous use.
이러한 목표를 달성하기 위하여, 본 발명자들은 자극성/독성이 없는 천연물 유래의 구조를 갖는 성분으로서, 모발 및 두피 조직과의 친화력이 우수한 동시에, 항산화, 항염, 항균 작용이 뛰어나, 모발 및 두피 조직에서 유해균의 번식, 염증발생, 산화스트레스를 보다 효과적으로 장시간 차단할 수 있는 성분을 찾기 위하여 노력한 바, 디벤조-p-디옥신 골격을 갖는 천연화합물이 이러한 조건들을 매우 잘 만족시킨다는 것을 발견하여 본 발명을 완성하였다
In order to achieve this goal, the present inventors have a structure derived from natural products that are not irritant / toxic, and have excellent affinity with hair and scalp tissue, and have excellent anti-oxidation, anti-inflammatory and antibacterial effects, and are harmful to hair and scalp tissue. Efforts have been made to find a component that can effectively block proliferation, inflammation, and oxidative stress in the long term, and have found that natural compounds having a dibenzo-p-dioxin skeleton satisfy these conditions very well.
탈모, 모발생장억제, 비듬생성, 염증, 가려움 증 등의 원천적 요인들 즉, 호르몬 불균형, 생활습관에 따른 다양한 스트레스 요인, 위생 상태에 의한 2차적 유해균 발생, 염증반응, 산화스트레스 등의 요인이 증가하게 되면, 이 들의 작용이 더욱 복합적으로 작용하여 알러지반응, 혈액순환 부진, 세포 대사 및 생장 억제 작용이 나타난다. 그리고 이러한 원인들에 의해 결국, 탈모, 모발생장억제, 비듬생성, 염증, 가려움 증 등의 현상이 발생된다. Increased factors such as hair loss, hair growth inhibition, dandruff production, inflammation, and itching, such as hormonal imbalance, various stressors according to lifestyle, secondary harmful bacteria caused by hygiene, inflammatory reaction, and oxidative stress When combined, their action is more complex, resulting in allergic reactions, poor blood circulation, cell metabolism and growth inhibition. In addition, these causes eventually cause hair loss, hair growth inhibition, dandruff production, inflammation, itching, and the like.
상기한 2차적 요인중 하나로서, 비듬의 원인이 되는 균(Malassezia restrica)이 최근 알려졌다(Christina M. Gemmer, Thomas L. Dawson Jr, et al., Journal of Clinical Microbiology, Sept Vol. 40, No. 9, p3350-3357(2002)). 이 균은 두피에 정상균총의 일부로 상존하고 있다가 스트레스, 기후변화, 땀, 음식 등의 환경적 유발요인에 의해 과대 증식될 경우, 비듬, 가려움증, 지루성 피부염을 유발시키는 것으로 보고 되었다(Bergbrant I. M. Seborrhoeic dermatitis and Pityrosporum yeasts. Current Topics in Medical Mycology. 6: 95-112(1995)). 또한, 비듬이 많이 발생하면 가려움 등으로 인해 두피를 과도하게 문지르게 되고, 이에 의해 상처가 생기거나 경우에 따라 서는 2차적 염증을 일으키기도 하며, 탈모의 원인이 되기도 한다. 현재 비듬치료제로서 항진균제인 케토코나졸(ketoconazole), 아연 피리치온(zinc pyrithion), 이트라코나졸(itraconazole), 피록톤올아민(Piroctone Olamine) 등이 주로 사용되고 있으나, 상기 항진균제들은 비듬치료에 좋은 효과를 나타내는 반면, 인위적으로 합성된 물질들이기 때문에 인체 안전성에 대한 의문이 제기되고 있다. 본 발명자들은 지속적인 연구에 의해 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체가 Malassezia restrica 균을 효과적으로 제어하면서도 안전하다는 것을 확인하였다. As one of the secondary factors mentioned above, Malassezia restrica has recently been known (Christina M. Gemmer, Thomas L. Dawson Jr, et al., Journal of Clinical Microbiology, Sept Vol. 40, No. 9, p3350-3357 (2002)). This bacteria has been reported to cause dandruff, itching and seborrheic dermatitis when it is present in the scalp as part of the normal flora and overproliferated by environmental factors such as stress, climate change, sweat and food (Bergbrant IM Seborrhoeic). dermatitis and Pityrosporum yeasts.Current Topics in Medical Mycology. 6: 95-112 (1995)). In addition, when a lot of dandruff occurs, the scalp is excessively rubbed due to itching, thereby causing a wound or, in some cases, causing secondary inflammation and causing hair loss. Currently, antifungal agents such as ketoconazole, zinc pyrithion, itraconazole, and pyroctone olamine are mainly used as anti-dandruff agents. As these are artificially synthesized materials, questions about human safety have been raised. The present inventors have continued to confirm that dibenzo-p-dioxine derivatives are safe while effectively controlling Malassezia restrica.
또한, 상기에서 기술된 2차적 요인 중 하나인 염증반응은 유해균의 자극에 의해서도 발생하지만, 이와 관계 없이 고칼로리와 운동부족으로 특징화 되는 서구화된 생활습관에 의한 대사성증후군에 의해서도 만성적으로 발생하며, 정신적인 스트레스나 쇼크에 의해 일시적으로 발생할 수도 있다. 염증반응은 조직의 퇴행화를 가속화 시키고, 세포생장을 억제하며, 면역체계를 과도하게 민감하게 함으로써 알러지 현상을 더욱 자극하는 등, 두피 및 모발 조직의 건강을 해치게 된다. 본 발명자들은 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체가 염증을 효과적으로 제어하면서도 안전하다는 것을 확인하였다. In addition, the inflammatory response, which is one of the secondary factors described above, is also caused by stimulation of harmful bacteria, but is also chronically caused by metabolic syndrome due to westernized lifestyle, which is characterized by high calorie and lack of exercise. It may be caused temporarily by mental stress or shock. Inflammatory reactions damage the health of the scalp and hair tissues by accelerating tissue degeneration, inhibiting cell growth, and stimulating allergies by making the immune system overly sensitive. The inventors have found that dibenzo-p-dioxine derivatives are safe while effectively controlling inflammation.
또한, 상기한 2차적 요인중 하나인 산화스트레스는 자외선, 공해물질의 작용에 의하여 발생하여, 두피 조직의 DNA, 세포막, 단백질을 공격하여 모발 및 두피 조직을 파괴하고, 염증을 일으킴으로써 두피 및 모발 건강을 해친다. 본 발명자들은 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체가 산화스트레스를 효과적으로 제어하면서도 안전하다는 것을 확인하였다.In addition, oxidative stress, which is one of the secondary factors, is caused by the action of ultraviolet rays and pollutants, attacking DNA, cell membranes, and proteins of the scalp tissue, destroying the hair and the scalp tissue, and causing inflammation. Harm your health. The present inventors have found that dibenzo-p-dioxine derivatives are safe while effectively controlling oxidative stress.
또한 이러한 2차적 요인들은 생활습관이나 환경에서부터 지속적으로 공급되어 끊임 없이 모발 및 두피를 자극하므로, 이러한 요인들이 두피 및 모발에 작용하는 기회를 최소화 시킬 수 있는 방법, 예를 들어 이러한 유해 요인들을 제어할 수 있으면서 동시에 두피 및 모발에 코팅이 되어 보다 효과적으로 방어할 수 있는 성분의 개발이 필요하다. 본 발명자들은 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체가 모발 친화력이 매우 우수하다는 것을 확인하였다.In addition, these secondary factors are constantly supplied from lifestyles and the environment, continually stimulating hair and scalp, so that these factors can minimize the chances of working on the scalp and hair, for example to control these harmful factors. At the same time, it is necessary to develop a component that can be coated on the scalp and hair to protect more effectively. The inventors have found that the dibenzo-p-dioxine derivative has a very good hair affinity.
상기한 요인들(유해균, 염증, 산화스트레스)은 서로 복합적으로 상승 작용하여 지속되고 더욱 심해지는 악순환을 초래함으로써 탈모촉진, 모발생장 억제, 과도한 비듬생성, 두피염증, 가려움증 등의 현상을 일으킨다. 따라서 상기와 같은 복합적인 요인들에 대하여 모두 우수한 효과를 제공하는 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 탈모촉진, 모발생장 억제, 과도한 비듬생성, 두피염증, 가려움증 등에 매우 우수한 효과를 제공한다.
The above factors (harmful bacteria, inflammation, oxidative stress) in combination with each other, causing a vicious cycle that continues and worsens, causing hair loss, hair growth inhibition, excessive dandruff, scalp inflammation, itching and the like. Therefore, dibenzo-p-dioxine derivatives, which provide excellent effects on all of these complex factors, are excellent in promoting hair loss, inhibiting hair growth, excessive dandruff production, scalp inflammation, and itching. Provide effect.
본 발명의 두피 및 모발 건강 개선용 조성물은, 기존의 항균, 항산화, 항염 활성을 갖는 화합물들이 자극성 및 독성이 강하여 반복 사용시, 두피 건강에 악영향을 끼치는 것과 달리, 독성이나 자극성이 없을 뿐만 아니라, 오히려 다른 성분에 의한 자극도 완화시키는 기능을 제공한다는 특징을 갖는다. 또한 두피와 모발 조직과의 친화력을 통하여 소량의 사용량으로도 두피와 모발 조직에 항균, 항산화, 항염 기능을 집중하는 것이 가능하므로, 위험요인(미생물, 활성산소, 염증반응)을 효과적으로 원천 차단하거나 제거한다는 특징을 갖는다. 또한, 기존의 항균제는 독성 및 자극성으로 인하여 두피 및 모발조직에 머무르는 신간을 최소화 해야 하며, 내성도 발생시키는 문제가 있으나, 본 발명의 조성물은 독성 및 자극성이 없으므로, 두피 및 모발 조직에서 미생물이 번식하지 못하도록 항균층을 형성하더라도 문제가 없으며, 내성도 발생되지 않는 특징을 갖는다.
The composition for improving scalp and hair health of the present invention, unlike conventional compounds having antimicrobial, antioxidant, and anti-inflammatory activity, has strong irritation and toxicity and thus adversely affects scalp health, it is not toxic or irritating, but rather It also has the feature of providing a function of relieving stimulation caused by other components. Also, due to the affinity between the scalp and the hair tissue, it is possible to concentrate the antibacterial, antioxidant and anti-inflammatory functions on the scalp and the hair tissue even with a small amount of use, thus effectively blocking or eliminating risk factors (microorganisms, free radicals, inflammatory reactions). It is characterized by. In addition, the existing antimicrobial agent should minimize the new stay in the scalp and hair tissue due to toxicity and irritation, but also has a problem of generating resistance, but the composition of the present invention is not toxic and irritant, so microorganisms in the scalp and hair tissue breeding There is no problem even if the antimicrobial layer is formed so as not to have any resistance.
본 발명에 있어서, 상기 디벤조-p-디옥신 유도체는 하기 화학식 1 내지 10으로 표시되는 화합물로 이루어진 군으로부터 선택되는 하나 이상의 화합물일 수 있다:In the present invention, the dibenzo-p-dioxin derivative may be one or more compounds selected from the group consisting of compounds represented by the following formula 1 to 10:
[화학식1][Formula 1]
[화학식2] (2)
[화학식3][Formula 3]
[화학식4][Formula 4]
[화학식5][Formula 5]
[화학식6][Formula 6]
[화학식7][Formula 7]
[화학식8][Formula 8]
[화학식9][Chemical Formula 9]
[화학식10][Formula 10]
상기 화학식1 내지 10에서, In Chemical Formulas 1 to 10,
R은 각각 독립적으로 수소, C1~C5의 알킬, C2~C5의 알케닐, 페닐, C7~C12의 페닐알킬, C2~C20의 알카노일, C3~C20의 알케노일, 히드록시페닐, 디히드록시페닐 또는 트리하이드록시페닐이다.R is independently hydrogen, C1-C5 alkyl, C2-C5 alkenyl, phenyl, C7-C12 phenylalkyl, C2-C20 alkanoyl, C3-C20 alkenoyl, hydroxyphenyl, dihydroxy Phenyl or trihydroxyphenyl.
상기에서 R은 각각 독립적으로 수소; 메틸; 에테닐; 벤질; 아세틸 또는 올레오일(oleoyl); 4-히드록시페닐; 2,4-히드록시페닐; 또는 2,4,6-트리히드록시페닐인 것이 바람직하다. 더욱 바람직하게는 수소이다.
R is each independently hydrogen; methyl; Ethenyl; benzyl; Acetyl or oleoyl; 4-hydroxyphenyl; 2,4-hydroxyphenyl; Or 2,4,6-trihydroxyphenyl. More preferably hydrogen.
본 발명의 두피 및 모발 건강 개선용 조성물에 있어서, 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 상기 화학식3, 화학식5, 화학식6 및 화학식8로 이루어진 군으로부터 선택되는 2종 이상의 화합물로 구성되는 것일 수 있으며, 이때 상기 화학식 3, 5, 6 및 8에서 R=H인 것이 바람직하다. In the scalp and hair health improving composition of the present invention, dibenzo-p-dioxine derivatives are two or more selected from the group consisting of Chemical Formulas 3, 5, 6 and 8 It may be composed of a compound, wherein R = H in the formula 3, 5, 6 and 8 is preferred.
상기에서 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 상기 유도체 총 중량에 대하여 화학식3의 화합물 10~60 중량%, 화학식5의 화합물 15~60 중량%, 화학식6의 화합물 10~40 중량% 및 화학식8의 화합물 5~30 중량%를 포함하여 구성될 수 있다. The dibenzo-p-dioxine derivatives are 10 to 60% by weight of the compound of Formula 3, 15 to 60% by weight of the compound of Formula 5, and 10 to 10% of the compound of Formula 6 based on the total weight of the derivative. 40 wt% and 5 to 30 wt% of the compound of Formula 8 may be included.
또한, 상기 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 유도체 총 중량에 대하여 화학식3의 화합물 12~38 중량%, 화학식5의 화합물 18~57 중량%, 화학식6의 화합물 10~30 중량% 및 화학식8의 화합물 10~30 중량%를 포함하여 구성되는 것이 더욱 바람직하다.
In addition, the dibenzo-p-dioxine derivative is 12 to 38% by weight of the compound of Formula 3, 18 to 57% by weight of the compound of Formula 5, 10 to 10 of the compound of Formula 6 based on the total weight of the derivative More preferably, it comprises 30% by weight and 10-30% by weight of the compound of the formula (8).
상기 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체는 상기 화학식3, 화학식5, 화학식6 및 화학식8로 이루어진 군으로부터 선택되는 2종 이상의 화합물 외에, 상기 화학식1, 화학식2, 화학식4, 화학식9 및 화학식10으로 이루어진 군으로부터 선택되는 1종 이상의 화합물을 더 포함하여 구성될 수 있다. 이 경우, 상기 화학식1, 화학식2, 화학식4, 화학식9 및 화학식10으로 이루어진 군으로부터 선택되는 1종 이상의 화합물은 상기 유도체 총 중량에 대하여 0.1~50 중량%로 포함되는 것이 바람직하다.
The dibenzo-p-dioxine derivative may be represented by Chemical Formula 1, Chemical Formula 2, Chemical Formula 4, in addition to two or more compounds selected from the group consisting of Chemical Formula 3, Chemical Formula 5, Chemical Formula 6 and Chemical Formula 8. It may be further comprises one or more compounds selected from the group consisting of Formula 9 and Formula 10. In this case, at least one compound selected from the group consisting of Chemical Formula 1, Chemical Formula 2, Chemical Formula 4, Chemical Formula 9 and Chemical Formula 10 may be included in an amount of 0.1 to 50 wt% based on the total weight of the derivative.
본 발명의 두피 및 모발 건강 개선용 조성물은 의학적 용도로서뿐만 아니라 화장료로서 사용될 수도 있다. 예컨대, 본 발명의 두피 및 모발 건강 개선용 조성물은 탈모 방지 및 모발의 생장 촉진용 의약품, 탈모 방지 및 모발의 생장 촉진 기능을 갖는 화장품 등을 포함한다. 상기에서 화장품은 구체적으로 두발 화장품을 의미하며, 샴푸, 린스, 로션, 토닉, 에센스, 비누, 젤, 무스 등을 들 수 있다. The composition for improving scalp and hair health of the present invention may be used not only as a medical use but also as a cosmetic. For example, the composition for improving scalp and hair health of the present invention includes pharmaceutical products for preventing hair loss and promoting hair growth, cosmetics having hair growth preventing and hair growth promoting functions, and the like. Cosmetics in the above means specifically hair cosmetics, shampoo, rinse, lotion, tonic, essence, soap, gel, mousse and the like.
본 발명의 두피 및 모발 건강 개선용 조성물은 의학 조성물 및 화장료 조성물 각 분야에서 통상적으로 사용되는 부형제와 함께 다양한 제형을 형성할 수 있다. The composition for improving scalp and hair health of the present invention may form various formulations with excipients commonly used in the medical and cosmetic compositions.
본 발명의 두피 및 모발 건강 개선용 조성물에 포함되는 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체의 1일 사용량은 1~100mg 정도가 바람직하다. 사용량이 상기의 범위에 한정되는 것은 아니다. 본 발명의 두피 및 모발 건강 개선용 조성물은 탈모예방, 모발의 생장 촉진, 비듬 방지, 두피염증 개선, 두피 가려움증 억제 등의 용도로 사용될 수 있다. 또한 상기 조성물은 모발 표면의 파괴 및 오염을 효과적으로 방지함으로써 모발 표면의 건강 증진 및 모발 관리를 용이하게 하는 용도로서도 사용될 수 있다.
The daily amount of the dibenzo-p-dioxine derivative included in the scalp and hair health improving composition of the present invention is preferably about 1 to 100 mg. The amount of use is not limited to the above range. The composition for improving scalp and hair health of the present invention can be used for preventing hair loss, promoting hair growth, preventing dandruff, improving scalp inflammation, inhibiting scalp itch and the like. In addition, the composition may be used as a use for facilitating health promotion and hair care of the hair surface by effectively preventing the destruction and contamination of the hair surface.
본 발명의 두피 및 모발 건강 개선용 조성물에 포함되는 디벤조-p-디옥신 유도체는 통상적인 모든 방법에 의해 얻을 수 있고, 시판되는 시약을 사용하여 합성 할 수도 있으며, 천연물 특히, 해조류로부터 추출 및 분리하여 얻을 수도 있다.
The dibenzo-VII-dioxin derivatives included in the scalp and hair health improving composition of the present invention can be obtained by all conventional methods, can be synthesized using commercially available reagents, and extracted from natural products, in particular, seaweeds. It can also be obtained separately.
이하에서, 실시예를 통하여 본 발명을 보다 상세히 설명한다. 그러나, 하기의 실시예는 본 발명을 더욱 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 하기의 실시예에 의하여 한정되는 것은 아니다. 하기의 실시예는 본 발명의 범위 내에서 당업자에 의해 적절히 수정, 변경될 수 있다.
Hereinafter, the present invention will be described in more detail with reference to Examples. However, the following examples are intended to further illustrate the present invention, and the scope of the present invention is not limited by the following examples. The following examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.
실시예 1: 디벤조-p-디옥신 유도체의 분리 정제Example 1 Separation and Purification of Dibenzo-VII-dioxin Derivatives
1-1: 갈조류로 부터 폴리페놀 혼합물의 추출1-1: Extraction of Polyphenol Mixtures from Brown Algae
대황(Eisenia bicyclis, 1kg)를 신선한 상태로 착즙기를 이용하여 섬유질을 제거한 후, 95% 에틸알코올(4L)을 추가하여 상온에서 30분간 교반하여 용액만을 걸러낸 후, 건조하여 58g의 갈색분말을 었었다. 얻어진 건조 분말을 20배량의 증류수(50℃)에 용해시킨 후, PVPP(Polyvinylpyrrolidone) 수지(상기 건조분말 중량의 10배)와 혼합하여 교반한 후(50℃, 1hr), 용액을 걸러내어 제거하고, 충분한 량의 증류수(중량비로 PVPP 수지의 5배 이상)로 세척하였다. 세척된 PVPP 수지에 95% 에탄올(중량비로 PVPP 수지의 3배량)을 더하여 상온에서 30분간 교반한 후, 걸러내고, 용액을 취하여 건조하여 8g의 흑갈색 분말을 얻었다. 폴린 시약을 사용하여 총 폴리페놀 함량을 측정한 결과 96.7%로 나타났다.
After removing rhubarb ( Eisenia bicyclis , 1kg) using a juicer in a fresh state, adding 95% ethyl alcohol (4L), stirring at room temperature for 30 minutes, filtering only the solution, and drying to obtain 58 g of brown powder. All. The obtained dry powder was dissolved in 20 times distilled water (50 ° C.), mixed with a polyvinylpyrrolidone (PVPP) resin (10 times the weight of the dry powder), stirred (50 ° C., 1hr), and the solution was filtered off. And washed with a sufficient amount of distilled water (more than 5 times of PVPP resin by weight). 95% ethanol (3 times the weight of PVPP resin in weight ratio) was added to the washed PVPP resin, stirred at room temperature for 30 minutes, filtered, and the solution was taken and dried to obtain 8 g of a dark brown powder. The total polyphenol content was measured using the Pauline reagent and found to be 96.7%.
1-2: 정제된 폴리페놀 혼합물로부터 디벤조-p-디옥신 유도체의 분리1-2: Separation of dibenzo-p-dioxin derivatives from purified polyphenol mixtures
상기 실시예1에서 얻은 폴리페놀 혼합물을 0.2㎛ 막여과지로 여과하여 고속 액체 크로마토그래피에 로딩(loading)하였다. 고속 액체 크로마토그래피에서, 컬럼은 HP ODS Hypersil 컬럼을, 용매로는 증류수와 메탄올을 사용하였으며, 용매의 공급은 1.0㎖/분의 유속으로 메탄올 15%에서 70%까지 30분간에 걸쳐 선형구배(linear gradient)를 걸어 10개의 활성물질을 분리하였다. 각 화합물은 화학식1 내지 10의 디벤조-p-디옥신 유도체임을 확인하였다.The polyphenol mixture obtained in Example 1 was filtered through a 0.2 μm membrane filter and loaded on high performance liquid chromatography. In high-performance liquid chromatography, the column was HP ODS Hypersil column, distilled water and methanol as solvent, and the supply of solvent was linear over 30 minutes from 15% to 70% methanol at a flow rate of 1.0 ml / min. 10 active materials were separated by a gradient. Each compound was identified to be a dibenzo-VII-dioxin derivative of Formulas 1-10.
[화학식1][Formula 1]
[화학식2] (2)
[화학식3][Formula 3]
[화학식4][Formula 4]
[화학식5][Formula 5]
[화학식6][Formula 6]
[화학식7][Formula 7]
[화학식8][Formula 8]
[화학식9][Chemical Formula 9]
[화학식10][Formula 10]
상기 화학식1 내지 10에서, R은 수소이다.
In Formulas 1 to 10, R is hydrogen.
실시예2: 모발친화력, 항산화, 항염 및 항균력 평가 실험Example 2: Evaluation of hair affinity, antioxidant, anti-inflammatory and antimicrobial activity
실시예1에서 분리된 디벤조-p-디옥신 유도체와 항산화, 항염 또는 항균력이 우수한 것으로 잘 알려진 천연성분인 퀘르세틴(quercetin), EGCG(Epigallocatechin gallate), 카테킨(catechin) 및 살리실산에 대하여 모발친화력, 항산화력, 항염활성, 항균력을 비교 평가 하고 그 결과를 하기 표1에 나타내었다.
Hair affinity to dibenzo-p-dioxin derivatives isolated in Example 1, and natural ingredients quercetin, EGCG (Epigallocatechin gallate), catechin and salicylic acid, which are well known for their excellent antioxidant, anti-inflammatory or antibacterial properties Antioxidative activity, anti-inflammatory activity, antimicrobial activity was evaluated and the results are shown in Table 1 below.
2-1: 모발친화력 평가2-1: Hair Affinity Evaluation
실시예1에서 분리된 디벤조-p-디옥신 유도체의 모발과의 친화력 평가를 다음과 같이 실시하였다. The affinity evaluation with the hair of the dibenzo-p-dioxin derivative isolated in Example 1 was performed as follows.
남성 5인 및 여성 5인의 이발에 의해 얻어진 모발(약 1cm 길이)을 각각 10g 씩 총 100g을 확보하여, 1mM TX-100 수용액(1L)에 넣고 상온에서 교반한 후, 세척액을 제거하고 남은 모발을 10L의 증류수를 사용하여 세척한 후, 40℃ 컨벡션 오븐(Convection Oven)에서 30분간 건조 하였다. 한편, 실시예1에서 분리된 디벤조-p-디옥신 유도체 각각의 시료를 DMSO에 녹여 0.1 wt% 가 되도록 샘플 용액을 만들었다. 10mL 의 인산완충용액(pH 7.0, 0.1mM)에 각각 30 마이크로리터의 샘플용액을 첨가하여 충분히 혼합한 후, 각각 1g의 준비된 모발을 첨가하여 40℃에서 10분간 격렬하게 교반 하였다. 모발이 첨가되지 않은 각 샘플용액에 대해서도 이와 동일한 과정을 수행하였다. 각각의 용액에서 용액 만을 뽑아 각각의 흡광도를 254nm, 25℃에서 측정하였다. A total of 100 g of hair (approximately 1 cm long) obtained by 5 male and 5 female haircuts were secured in total, 10 g each, and placed in a 1 mM TX-100 aqueous solution (1 L) and stirred at room temperature. After washing with 10 L of distilled water, it was dried for 30 minutes in a 40 ℃ convection oven (Convection Oven). Meanwhile, a sample solution of each of the dibenzo-p-dioxin derivatives separated in Example 1 was dissolved in DMSO to make 0.1 wt%. 30 microliters of sample solution was added to 10 mL of phosphate buffer solution (pH 7.0, 0.1 mM), and the mixture was sufficiently mixed. Then, 1 g of prepared hair was added and stirred vigorously at 40 ° C. for 10 minutes. The same procedure was followed for each sample solution without hair. Only the solution was withdrawn from each solution, and the respective absorbances were measured at 254 nm and 25 ° C.
각 샘플에 대하여, 모발과의 상호작용이 존재하지 않는 상태에서의 용액의 흡광도를 A100 로 하고, 상호작용이 있는 상태에서의 흡광도를 A로 하여, 다음 식을 이용하여 각 샘플의 모발친화력을 계산하여 하기 표 1에 나타내었다.For each sample, the absorbance of the solution in the absence of interaction with the hair is A100, and the absorbance in the presence of the interaction is A, and the hair affinity of each sample is calculated using the following equation. It is shown in Table 1 below.
모발친화력(%) = 100 X(A100-A)/A100
Hair Affinity (%) = 100 X (A100-A) / A100
2-2: 항산화력 평가2-2: Antioxidant Evaluation
실시예1에서 분리된 디벤조-p-디옥신 유도체에 대한 항산화력 평가를 다음과 같이 실시하였다. Antioxidant activity evaluation of the dibenzo-p-dioxin derivative isolated in Example 1 was carried out as follows.
DPPH 시약 2 mg을 정확히 칭량하여 EtOH 15 ml에 녹인 용액 1.2 ml에 다시 EtOH 3 ml와 DMSO 0.5 ml를 혼합하여 DPPH 용액을 제조하였다. 그리고 평가하고자 하는 각 시료를 DMSO에 녹여 100㎍/ml의 농도가 되도록 각각의 시료 용액을 제조하였다. 각각의 시료용액 50 ㎕와 제조한 DPPH용액을 혼합하여 10분간 상온에서 반응시킨 후 518 nm에서 흡광도를 측정하였다. 시료를 첨가하지 않은 대조군의 흡광도를 A0, 시료를 첨가한 용액의 흡광도를 A로 하고, 아래 식에 의하여 DPPH 라디칼 소거 활성을 계산하여 하기 표 1에 나타내었다.
2 mg of DPPH reagent was accurately weighed, and 1.2 ml of a solution dissolved in 15 ml of EtOH was mixed again with 3 ml of EtOH and 0.5 ml of DMSO to prepare a DPPH solution. Each sample solution to be evaluated was dissolved in DMSO to prepare a respective sample solution so as to have a concentration of 100 µg / ml. 50 μl of each sample solution and the prepared DPPH solution were mixed and reacted at room temperature for 10 minutes, and then absorbance was measured at 518 nm. The absorbance of the control group without adding the sample is A0, and the absorbance of the solution to which the sample is added is A, and the DPPH radical scavenging activity is calculated by the following equation and is shown in Table 1 below.
DPPH 라디칼 소거활성(%)= 100 X(A0-A)/A0
DPPH radical scavenging activity (%) = 100 X (A0-A) / A0
2-3: 항염효과 평가2-3: Anti-inflammatory effect evaluation
실시예1에서 분리된 디벤조-p-디옥신 유도체에 대한 항염 효과 평가를 다음과 같이 실시하였다. 마우스 대식세포 RAW 264.7(Korean Cell Line Bank)를 DMEM(10% fetal bovine serum and 1% penicillin/streptomycin)배지를 사용하여 37℃, 5% CO2(fully humidified air)에서 배양하였다. 배양된 세포를 96-well plates(200 마이크로리터/웰)로 옮기고 LPS(E. coli, serotype 055:B5, 최종농도 1 mg/mL) 및 DMSO에 녹여 100㎍/ml의 농도가 되도록 미리 만들어 놓은 각각의 시료용액 (최종 농도= 10㎍/mL)을 첨가 하여 18시간 동안 배양하였다. LPS 를 처리하지 않은 용액은 음성대조군, LPS를 처리하되 시료대신 생리식염수를 처리한 용액을 양성대조군으로 사용하였다. 상등액을 분리한 후, 염증반응의 정도를 표시해 주는 PGE2 농도(pg/mL)를 EIA 키트 제조사(Cayman Chemical Co.)에서 제시한 가이드에 따라 측정하여 다음 식에 따라 상대적인 항염증효과(%)를 계산하고, 하기의 표1에 나타내었다. The anti-inflammatory effect of the dibenzo-p-dioxin derivative isolated in Example 1 was evaluated as follows. Mouse macrophage RAW 264.7 (Korean Cell Line Bank) was incubated in DMEM (10% fetal bovine serum and 1% penicillin / streptomycin) medium at 37 ° C., 5% CO 2 (fully humidified air). The cultured cells were transferred to 96-well plates (200 microliters / well) and dissolved in LPS (E. coli, serotype 055: B5, final concentration of 1 mg / mL) and DMSO and prepared at a concentration of 100 µg / ml. Each sample solution (final concentration = 10 μg / mL) was added and incubated for 18 hours. For the solution not treated with LPS, a negative control group, LPS treatment, but a solution treated with saline instead of the sample was used as a positive control group. After separating the supernatant, the PGE2 concentration (pg / mL) indicating the degree of inflammatory response was measured according to the guide provided by the EIA kit manufacturer (Cayman Chemical Co.), and the relative anti-inflammatory effect (%) was calculated according to the following equation. It was calculated and shown in Table 1 below.
양성대조군에서의 PGE2 농도를 CM, 음성대조군에서의 PGE2 농도를 C0, 각 시료처리시의 PGE2 농도를 C라고 했을때,
When PGE2 concentration in the positive control group was CM, PGE2 concentration in the negative control group was C0, and PGE2 concentration at each sample treatment was C.
항염증효과(%) = 100 X(CM-C)/(CM-C0)
Anti-inflammatory effect (%) = 100 X (CM-C) / (CM-C0)
2-4.항균 활성 측정2-4.Antibacterial activity measurement
실시예1에서 분리된 디벤조-p-디옥신 유도체의 항균력 평가를 평판배지 확산법(Agar diffusion method)을 이용하여 비듬의 원인균인 Malassezia restricta 진균에 대한 억제활성을 측정하는 것에 의하여 수행하였다. 항균활성은 각 시료가 함유된 종이 디스크(paper disk)를 사용하여 평판배지 확산법으로 수행하였다. 우선, Malassezia restricta 균주를 배양배지(Modified Leeming and Notman agar medium, 0.1% polypeptone, 2.0% glucose, 5.0% Malt extract, 2.0% desiccated ox bile, 0.2% glycerol, 1.0% Tween 40 및 2.0% agar in distilled water)를 이용하여 36℃의 조건에서 배양하였다. 한편, 각각의 시료 5 mg을 에탄올 50 ㎕에 녹인 후, 직경 8mm, 두께 1.5mm의 환형 종이에 전체적으로 골고루 퍼지도록 흡수시키고, 용매를 완전히 증발시킨 다음, 배양한 말라세지아 진균의 균주가 접종된 mLNA(Modified Leeming and Notman agar medium) 평판배지에 올려 항균활성을 시험하였다. 상기와 같은 배양 조건에서 48시간 배양한 다음, 각각의 시료가 함침된 종이디스크 주변에 형성된 원형의 발육 저지환의 직경(mm)을 측정한 후, 디스크의 직경(8mm)을 빼고 2로 나눈 값(저해반경)으로 상대적인 항균력을 비교하였다. 결과는 하기 표1에 나타내었다.Evaluation of the antimicrobial activity of the dibenzo-p-dioxin derivative isolated in Example 1 was carried out by measuring the inhibitory activity against Malassezia restricta fungi, the causative agent of dandruff, using the Agar diffusion method. Antibacterial activity was carried out by plate medium diffusion method using a paper disk containing each sample. First, Malassezia restricta strains were cultured (Modified Leeming and Notman agar medium, 0.1% polypeptone, 2.0% glucose, 5.0% Malt extract, 2.0% desiccated ox bile, 0.2% glycerol, 1.0% Tween 40 and 2.0% agar in distilled water Cultured at 36 ° C. Meanwhile, 5 mg of each sample was dissolved in 50 μl of ethanol, and then absorbed to spread evenly on a circular paper having a diameter of 8 mm and a thickness of 1.5 mm, and the solvent was completely evaporated, followed by inoculation of the cultured Malassezia fungi. The antimicrobial activity was tested in mLNA (Modified Leeming and Notman agar medium) plate medium. After 48 hours of incubation in the above culture conditions, the diameter of the circular growth-resistant ring formed around the paper disc impregnated with each sample was measured, and then the diameter of the disc (8 mm) was subtracted by 2 ( Relative antimicrobial activity was compared. The results are shown in Table 1 below.
(%)Hair affinity
(%)
실시예3: 조성물의 제조Example 3 Preparation of Composition
상기 실시예 1 및 2로부터 디벤조-p-디옥신 유도체들이 모발친화력, 항균력, 항염 효과 및 항산화 효과에 있어서 모두 우수함을 확인하였다. 특히 모발 친화력, 항균력 및 항염 효과는 다른 천연물에 비하여 현저하게 우수하였다. 항산화 효과 또한 최고 수준을 나타내었다. 이러한 결과로부터 본 발명의 디벤조-p-디옥신 유도체들은 각각 사용하여도 두피와 모발 건강 개선에 뛰어난 효과를 보일 것으로 기대되었다. 그리고, 그 들 간의 조합을 통하여 더욱 우수한 효과를 나타낼 것으로 기대되었다. 따라서 각 활성이 뛰어난 성분들을 선정하여 조성물 1 내지 5를 제조하였다. 각 조성물의 화학적 조성은 하기 표2와 같다.It was confirmed from Examples 1 and 2 that the dibenzo-p-dioxin derivatives are all excellent in hair affinity, antibacterial activity, anti-inflammatory effect and antioxidant effect. In particular, hair affinity, antimicrobial activity and anti-inflammatory effect were remarkably superior to other natural products. Antioxidant effect also showed the highest level. From these results, it was expected that the dibenzo-p-dioxin derivatives of the present invention would have an excellent effect on improving scalp and hair health. And it was expected to show a better effect through the combination between them. Therefore, Compositions 1 to 5 were prepared by selecting components having excellent activity. The chemical composition of each composition is shown in Table 2 below.
(화학식1내지 10에서 R=H이고, 하기 비율은 중량비임)Composition of the sample
(R = H in formula 1 to 10, the following ratio is the weight ratio)
= 50:15:10:10:15Formula 3: Formula 5: Formula 6: Formula 8: Formula 10
= 50: 15: 10: 10: 15
= 5:5:20:3:25:15:8:12:2:5Chemical Formula 1: Chemical Formula 2: Chemical Formula 3: Chemical Formula 4: Chemical Formula 5: Chemical Formula 6: Chemical Formula 7: Chemical Formula 8: Chemical Formula 9: Chemical Formula 10
= 5: 5: 20: 3: 25: 15: 8: 12: 2: 5
실시예4: 상기 조성물의 모발 생장 촉진 효과 평가Example 4: Evaluation of the hair growth promoting effect of the composition
본 발명에 의한 조성물의 모발 생장 효과를 테스트하였다. 생후 7주된 마우스(C57BL/6)의 등 부위 털을 제거하고, 등 부위 피부가 깨끗한 것을 골라 물질군마다 5마리씩을 선정하여 매일 상기 실시예 3의 1~5의 조성물을 각각의 마우스 그룹 개체 당 150㎕씩 21일간 도포하였다. 비교군으로는 실시예 2의 비교시료 중 비교적 우수한 효과를 나타낸 EGCG, 음성대조군으로는 아무런 시료도 함유하지 않도록 하여 물/에탄올/1,3-부틸렌글리콜(부피비: 5/3/2)로 구성된 용매를 사용하였다. 도포 시작 23일 후, 새롭게 자라 올라온 털의 무게를 측정하여 음성대조군과 비교하였으며, 그 결과를 하기 표 3에 나타내었다.The hair growth effects of the compositions according to the invention were tested. 7 weeks old mouse (C57BL / 6) was removed from the back of the hair region, and the back skin was selected to select the five to each material group to clean the composition of Examples 1 to 5 of each mouse group each day 150 μl was applied for 21 days. In the comparative group, EGCG which showed a relatively good effect in the comparative sample of Example 2, and the negative control group to contain no sample, so as to water / ethanol / 1, 3- butylene glycol (volume ratio: 5/3/2) A configured solvent was used. 23 days after the start of application, the weight of the newly grown hair was measured and compared with the negative control group, and the results are shown in Table 3 below.
표 3에서 알 수 있는 바와 같이, 본 발명에 의한 조성물 및 EGCG를 함유한 경우 일반 용액(물/에탄올/1,3-부틸렌글리콜)을 바른 군보다 높은 모발무게 평균값을 나타내었다. 특히, 모발 친화력이 높은 성분이 최소화된 조성물5에 비하여 모발친화력이 높은 성분들이 높게 함유된 조성물 1~4가 전반적으로 높은 모발 성장 촉진 효과가 있음을 확인할 수 있었다. 모발친화력, 항산화력, 항염 및 항균력이 균형을 맞춘 조성1이 모발 성장 촉진 효과가 가장 우수하였다.
As can be seen from Table 3, when the composition according to the present invention and EGCG were contained, the average value of hair weight was higher than that of the group coated with the general solution (water / ethanol / 1,3-butylene glycol). In particular, it was confirmed that the compositions 1 to 4 containing high components of high hair affinity generally have a high hair growth promoting effect as compared to the composition 5 having a high component of high affinity for hair. Composition 1, which had a balance of hair affinity, antioxidant power, anti-inflammatory and antibacterial activity, had the best hair growth promoting effect.
실시예5: 상기 조성물의 두피 염증 완화 및 억제 효과 측정Example 5 Determination of Scalp Inflammation and Inhibitory Effect of the Composition
상기 조성물의 염모제의 자극에 의한 두피 염증 완화 및 억제 효과를 측정 하기 위하여 MEST(Mouse Ear Swelling Test)법을 응용하였다. 이를 위하여 실시예 3의 조성물 1~5를 사용하였으며, 비교군으로 EGCG를 사용하였다. MEST (Mouse Ear Swelling Test) method was applied to measure the effect of inhibiting and inhibiting scalp inflammation by stimulation of the hair dye of the composition. To this end, compositions 1 to 5 of Example 3 were used, and EGCG was used as a comparative group.
동물로는 6-8 주령 암컷 CF-1 마우스를 사용하였다. 마우스는 약 2주간의 적응기간을 거쳐서 모두 7개의 그룹으로 나뉘었으며, 각 그룹 당 10마리로 하였다. 동물실험실은 20±2℃, 습도 50±10%를 유지하면서 12시간 주기로 빛을 조절 하였다. 전 실험기간을 통하여 동물식이 공급 되었으며 물은 자유로이 마실 수 있도록 하였다.As animals, 6-8 week old female CF-1 mice were used. Mice were divided into seven groups after approximately two weeks of acclimatization, with 10 animals in each group. The animal laboratory was controlled to light at a 12 hour cycle while maintaining a humidity of 20 ± 2 ℃, 50 ± 10%. Animal food was supplied throughout the entire experimental period and water was freely available for drinking.
쥐의 복부 부위에 털을 제거하고, 25㎕의 Freund's complete adjuvant(FCA)를 복부 피부내 진피층에 2번 주사하였다. 마우스 복부 피부의 각질층을 강력테이프를 이용하여 제거 한후, 100㎕의 염모제를 쥐의 복부 피부내에 도포한 다음 30분 지난 후, 같은 양의 상기 조성물 1~5 혹은 비교물질을 피부에 도포하였다. 3일 후 같은 실험을 반복하였다. 실험을 시작한지 6일이 지난후, 스웰링 된 귀 (ear swelling)의 두께 및 스웰링 발생 빈도를 측정하였다.Hair was removed from the abdomen of the rat, and 25 μl of Freund's complete adjuvant (FCA) was injected twice into the dermal layer of the abdominal skin. After removing the stratum corneum of the mouse abdominal skin with strong tape, 100 μl of hair dye was applied to the abdominal skin of the mouse, and after 30 minutes, the same amount of the composition 1 to 5 or the comparative material was applied to the skin. The same experiment was repeated after 3 days. Six days after the start of the experiment, the thickness of the swelling ear (ear swelling) and the frequency of swelling occurrence were measured.
표 4에서 알 수 있는 바와 같이, 본 발명에 의한 상기 조성물을 염모제와 함께 처리 한 경우 귀의 스웰링 빈도가 현저히 줄어 들었음을 알수 있으며 귀의 두께도 유의성 있게 감소하여 염증을 완화시키는 효과가 있음을 확인할 수 있었다. 이로써 본 발명에 의한 조성물이 염모제에 의한 염증을 완화시키는 효과가 있는 것으로 판단할 수 있다.
As can be seen from Table 4, when the composition according to the present invention is treated with a hair dye, it can be seen that the swelling frequency of the ear is significantly reduced, and the thickness of the ear is also significantly reduced, thereby confirming the effect of alleviating inflammation. there was. Thereby, it can be judged that the composition by this invention has the effect of alleviating the inflammation by a hair dye.
실시예6: 두피 가려움증Example 6 Scalp Itching
본 발명에 의한 조성물의 가려움 억제 효과를 테스트하였다. 실시예 3의 조성물 1~5 및 비교물질(EGCG)의 피부 적용을 쉽게 하기 위해서 무모생쥐를 사용하였다. 무모생쥐는 모두 7주령의 수컷을 이용하였고, 각 군당 10마리를 사용하였다. 조성물 1~3 혹은 비교물질 100㎕ 를 1일 2회 5일간 처리한 후 가려움 유발 물질(Compound 48/80)을 생리식염수에 1㎎/㎖ 농도로 녹여서 진피층 내에 주사 하였다. 주사가 끝나면 곧바로 관찰용 우리에 무모생쥐를 넣은 후 30분간 비디오로 촬영하여, 뒷다리로 가려움 부위를 긁는 횟수를 측정하여 숫자로 표시하였다. 앞발로 긁거나 입으로 물어뜯는 행동은 제외하고 오직 뒷발로 주사부위를 긁는 행동만을 가려움 행동의 지표로 간주하여 측정하였고, 측정결과를 하기 표 5에 나타내었다.The anti-itch effect of the composition according to the present invention was tested. Hairless mice were used to facilitate skin application of Compositions 1-5 and Comparative Material (EGCG) of Example 3. All hairless mice were males of 7 weeks old, and 10 mice were used in each group. After treating the composition 1 to 3 or 100 μl of the comparative substance twice a day for 5 days, itching substance (Compound 48/80) was dissolved in physiological saline at a concentration of 1 mg / ml and injected into the dermal layer. Immediately after the injection, the hairless mice were placed in the cage for observation and photographed for 30 minutes, and the number of scratches on the itch with the hind legs was measured and displayed in numbers. Except for scratching by the forefoot or biting by mouth, only the action of scratching the injection site with the hind feet was considered as an indication of the itch behavior, and the measurement results are shown in Table 5 below.
표 5에서 알 수 있는 바와 같이, 본 발명에 의한 실시예 3의 조성물 1~5로 전처리한 경우 긁은 횟수가 감소하여 가려움을 억제하는 효과가 있음을 확인할 수 있다.
As can be seen in Table 5, when the pre-treatment with the composition 1 to 5 of Example 3 according to the present invention can be confirmed that the number of scratches to reduce the effect of suppressing itching.
실시예7: 제형물의 제조Example 7: Preparation of Formulations
In vivo 실험에서 전반적으로 우수한 효과를 나타낸 상기 조성물들을 일상 생활에서 실제 두피 및 모발에 적용할 수 있도록 여러가지 종류의 제형으로 제조하였다. The compositions, which showed overall excellent effects in the in vivo experiments, were prepared in various types of formulations to be applied to actual scalp and hair in daily life.
7-1: 하기 표6의 조성으로 헤어토닉 제조 7-1: Hair tonic preparation with the composition shown in Table 6 below
7-2: 하기 표7의 조성으로 헤어샴푸 제조7-2: hair shampoo in the composition shown in Table 7 below
7-3: 하기 표8의 조성으로 헤어린스 제조 7-3: Hairliner prepared by the composition of Table 8 below
7-4: 하기 표9의 조성으로 헤어로션 제조 7-4: Hair lotion was prepared using the composition shown in Table 9 below.
실시예 8. 탈모 방지 효과(헤어토닉) 평가Example 8. Hair loss prevention effect (hair tonic) evaluation
초기 탈모 현상이 있는 피검자 20명을 대상으로 탈모 방지 효과에 관한 실험을 12주 동안 진행하였다. 상기 실시예 7의 7-1의 제형예1 및 비교예1, 비교예2의 헤어토닉을 1일 1회씩 12주 동안 사용한 후, 12주가 경과한 다음 머리를 감을 때 다시 탈락모를 수집하여 개수를 세어 그 결과를 하기 표 10에 나타내었다.Twenty subjects with initial hair loss were tested for anti-hair loss for 12 weeks. After the hair tonic of Formulation Example 1, Comparative Example 1, and Comparative Example 2 of Example 7-1 of Example 7 for 12 weeks once a day, after 12 weeks have elapsed after collecting the hair loss hairs to collect the number The results are shown in Table 10 below.
표 10에서 알 수 있는 바와 같이, 본 발명에 의한 제형예1의 헤어토닉으로 처리할 경우 비교예 1 또는 2를 처리한 경우와 비교하여 탈락모의 개수가 유의성 있게 감소하는 것을 확인하였다.
As can be seen in Table 10, it was confirmed that the treatment of the hair tonic of the formulation example 1 according to the present invention significantly reduced the number of hair loss compared to the case of treating the comparative example 1 or 2.
실시예9: 비듬 생성 방지 및 가려움증 예방 효과 평가Example 9 Evaluation of Prevention of Dandruff and Itching Prevention
9-1: 비듬방지효과 측정9-1: Anti-dandruff effect measurement
상기 실시예7의 7-2의 헤어샴푸(제형예2, 비교예3, 또는 비교예4)에 대하여 비듬생성 방지 효과를 측정하였다. The anti-dandruff production effect was measured for the hair shampoo (Formulation Example 2, Comparative Example 3, or Comparative Example 4) of 7-2 of Example 7.
비듬이 비교적 많은 남녀 10명을 선정하여 시험 개시전에 통상의 샴푸로 세발하고 3일간 누적된 비듬을 채집하여 채집된 비듬의 중량과, 상기 조성물(제형예2), 살리실산(비교예3) 또는 EGCG(비교예4)가 함유된 헤어샴푸 물로 1개월간 세발하고 3일간 누적된 비듬의 중량을 비교 평가하였다.Ten men and women with relatively high dandruff were selected, triturated with a conventional shampoo before the start of the test, and the dandruff accumulated for 3 days was collected, and the weight of the collected dandruff, the composition (Formulation Example 2), salicylic acid (Comparative Example 3) or EGCG The hair shampoo containing (Comparative Example 4) was triturated for 1 month and the weight of the dandruff accumulated for 3 days was evaluated.
이때 누적된 비듬의 채취는 피시험자들의 두피를 통상의 샴푸 5g정도를 사용하여 시험자로 하여금 세척하게 한 다음, 약 2 내지 3리터의 물로 씻어내게 하였다. 씻어낸 물을 800마이크로 공극크기의 여과체로 거른다음 여과체위의 비듬의 건조중량을 측정하였고, 다음의 식에 의해 비듬감소율을 구하였고 피시험자가 느끼는 비듬개선효과를 설문으로 조사하였으며, 이를 하기 표 11에 나타내었다.At this time, the collection of the accumulated dandruff was allowed to test the scalp of the test subjects using about 5g of normal shampoo, and then washed with about 2 to 3 liters of water. The washed water was filtered through a 800 microporous filter, and the dry weight of dandruff on the filter was measured. The rate of dandruff reduction was determined by the following equation. 11 is shown.
비듬감소율(%)=[(시험개시전 비듬의 중량(㎎)-시험개시 1개월 후 비듬의 중량(㎎))/시험개시전의 비듬의중량(㎎)]×100Dandruff reduction rate (%) = [(weight of dandruff before test start-mg weight of dandruff after start of test (mg)) / weight of dandruff before start of test (mg)] x 100
표 11에서 알 수 있는 바와 같이, 본 발명에 의한 제형예2의 헤어샴푸로 처리할 경우 비교예 3 또는 4로 처리한 경우와 비교하여 비듬방지 효과가 유의성 있게 증가함을 확인하였다.
As can be seen in Table 11, the hair shampoo of the formulation example 2 according to the present invention was confirmed to significantly increase the anti-dandruff effect compared to the case of treatment with Comparative Example 3 or 4.
9-2: 가려움증 방지효과 평가9-2: Evaluation of Itching Prevention Effect
상기 실시예7의 7-2의 헤어샴푸(제형예2, 비교예3 또는 비교예4)에 대하여 가려움증 방지 효과를 측정하였다. The anti-itch effect was measured for the hair shampoo (Formulation Example 2, Comparative Example 3 or Comparative Example 4) of 7-2 of Example 7.
평소 가려움을 많이 느끼는 남녀를 선정하여 제형예2, 비교예3 또는 비교예4의 제품을 각 제품당 10명씩 2일 1회씩 8주간 사용하게 한후, 면접을 통하여 하기 표12의 평가기준에 따라 평가하였고, 표13에 평점의 평균으로 나타내었다.Men and women who usually feel itching to use the product of Formulation Example 2, Comparative Example 3 or Comparative Example 4 for 8 weeks, once every two days, 10 people per product for 8 weeks, and then evaluated in accordance with the evaluation criteria of Table 12 below through an interview In Table 13, the average of the ratings is given.
표13에서 알 수 있는 바와 같이, 본 발명에 의한 제형예2의 헤어샴푸로 처리할 경우 비교예 3 또는 4로 처리한 경우와 비교하여 비듬방지 두피가려움 억제 효과가 유의성 있게 증가함을 확인하였다.
As can be seen in Table 13, when the hair shampoo of Formulation Example 2 according to the present invention it was confirmed that compared to the case of treatment with Comparative Example 3 or 4 it was confirmed that the anti-dandruff scalp itching effect significantly increased.
실시예 10. 사용감 개선 효과 평가Example 10. Evaluation of Usability Improvement Effect
25~50세의 여성 20명을 대상으로 실시예7의 7-2의 헤어샴푸(제형예2, 비교예3 또는 비교예4)를 일반적인 사용법에 따라 모발에 사용하게 하고, 건조 30분 후 에 느껴지는 윤기, 매끄러움, 빗질감에 대한 만족도를 평가하게 하였다. 또한 12시간 후에 느껴지는 윤기, 매끄러움, 빗질감에 대한 만족도도 평가하게 하였다. 각 참여자는 1주일 간격으로 3가지 다른 샴푸를 모두 사용하게 하되, 어떤 종류의 샴푸인지 알 수 없게 하였다. Twenty females 25 to 50 years old were used to use the hair shampoo (Formulation Example 2, Comparative Example 3 or Comparative Example 4) of Example 7 on the hair according to the general usage, and after 30 minutes of drying, Satisfaction with feeling of gloss, smoothness and combing was evaluated. We also evaluated the satisfaction with the shine, smoothness and combing felt after 12 hours. Each participant asked to use all three different shampoos at weekly intervals, but did not know what kind of shampoo they were.
만족도 평가는 각 항목에 대하여 가장 높은 수준은 5, 가장 낮은 수준은 1로 하여 5,4,3,2,1 중 한가지를 선택하도록 하였다. 각 항목당 평가점수의 평균을 비교하여 아래 표14에 나타내었다. 사용 직 후에는 모든 샴푸의 만족도가 전반적으로 높았으며, 제형예2의 샴푸 사용의 경우가 만족도가 상대적으로 높았다. 그러나 12시간 경과후의 윤기, 매끄러움 및 빗질감에 있어서 비교예 3 및 4의 샴푸를 사용한 경우, 만족감이 현저하게 감소한 반면, 제형예2를 사용한 경우, 만족감이 매우 높은 수준에서 유지 되었다. 따라서 본 발명의 조성물이 모발의 만족스러운 촉감을 획기적으로 장시간 유지시킨다는 것을 알 수 있다.For the satisfaction evaluation, the highest level was 5 and the lowest level was 1 for each item, and one of 5, 4, 3, 2, and 1 was selected. The average of the evaluation scores for each item is shown in Table 14 below. Immediately after use, the satisfaction of all shampoos was high overall, and the use of shampoos of Formulation Example 2 was relatively high. However, when the shampoos of Comparative Examples 3 and 4 were used in the gloss, smoothness, and combing after 12 hours, the satisfaction was remarkably decreased, whereas when using Formulation Example 2, the satisfaction was maintained at a very high level. Thus, it can be seen that the composition of the present invention maintains a satisfactory touch of hair significantly for a long time.
Claims (12)
[화학식3]
[화학식5]
[화학식6]
[화학식8]
상기 식들에서 R은 H이다.To prevent hair loss, characterized in that it comprises at least two dibenzo-p-dioxine derivatives selected from the group consisting of compounds represented by the formula (3), (5), (6) and (8) Cosmetic composition for promoting hair growth:
[Formula 3]
[Formula 5]
[Formula 6]
[Formula 8]
R is H in the above formulas.
[화학식1]
[화학식2]
[화학식4]
[화학식9]
[화학식10]
상기 식들에서 R은 H이다.The method of claim 5, wherein the cosmetic composition for preventing hair loss and promoting hair growth is at least one dibenzo-p- selected from the group consisting of compounds represented by the following Chemical Formulas 1, 2, 4, 9 and 10: A cosmetic composition for preventing hair loss and promoting hair growth, further comprising a dibenzo-p-dioxine derivative:
[Chemical Formula 1]
(2)
[Formula 4]
[Formula 9]
[Chemical formula 10]
R is H in the above formulas.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009811A KR101201524B1 (en) | 2010-02-03 | 2010-02-03 | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives |
PCT/KR2011/000654 WO2011096688A2 (en) | 2010-02-03 | 2011-01-31 | Composition for improving scalp and hair health comprising a dibenzo-p-dioxin derivative |
JP2012551913A JP5694382B2 (en) | 2010-02-03 | 2011-01-31 | Composition for preventing hair loss and promoting hair growth comprising a dibenzo-p-dioxin derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009811A KR101201524B1 (en) | 2010-02-03 | 2010-02-03 | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120031293A Division KR101220508B1 (en) | 2012-03-27 | 2012-03-27 | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110090174A KR20110090174A (en) | 2011-08-10 |
KR101201524B1 true KR101201524B1 (en) | 2012-11-14 |
Family
ID=44355936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100009811A KR101201524B1 (en) | 2010-02-03 | 2010-02-03 | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5694382B2 (en) |
KR (1) | KR101201524B1 (en) |
WO (1) | WO2011096688A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2988764T3 (en) * | 2013-08-22 | 2018-08-31 | Lucas Meyer Cosmetics Canada Inc. | Anti-dandruff compositions, and methods of use thereof |
CN109276466A (en) * | 2017-07-21 | 2019-01-29 | 博塔医疗株式会社 | It is effective component for preventing white hair and promoting the composition and product of dark hair using brown algae polyphenols |
KR102192712B1 (en) * | 2018-01-25 | 2020-12-18 | 주식회사 헤마스 | An animal feed composition comprising phlorotannin and product for animal |
CN113194743A (en) * | 2018-12-05 | 2021-07-30 | 博塔医疗株式会社 | Composition for improving food flavor comprising brown algae polyphenol as effective ingredient |
KR102144990B1 (en) * | 2019-04-24 | 2020-08-14 | 한국과학기술연구원 | Acrylate compound, polymer formed from the acrylate compound, and polyacrylate film containing the polymer |
CN111018874B (en) * | 2019-11-25 | 2021-06-22 | 武汉华星光电半导体显示技术有限公司 | Hole transport material, preparation method thereof and organic light emitting diode device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879558B1 (en) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | Skin protection and improvement agent containing dibenzo 함유 paradioxin derivative as an active ingredient |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3652382B2 (en) * | 1994-04-11 | 2005-05-25 | 株式会社ナリス化粧品 | Testosterone-5α-reductase inhibitor |
KR100363112B1 (en) * | 2000-04-27 | 2002-12-05 | 벤트리 주식회사 | Novel Material Separated from Ecklonia cava, The Method for Extracting and Purifying the Same, And The Use Thereof for Antioxidants |
KR20020025358A (en) * | 2000-09-28 | 2002-04-04 | 이 행 우 | Composition for growing hair and method of preparation thereof |
JP2007131571A (en) * | 2005-11-10 | 2007-05-31 | Ichimaru Pharcos Co Ltd | Hair papilla cell proliferation enhancer |
JP2007217339A (en) * | 2006-02-16 | 2007-08-30 | Kanehatsu Foods Co Ltd | Antiallergic substances |
JP2010013429A (en) * | 2008-07-01 | 2010-01-21 | Takashi Suzuki | Scalp preparation for external use |
-
2010
- 2010-02-03 KR KR1020100009811A patent/KR101201524B1/en active IP Right Grant
-
2011
- 2011-01-31 WO PCT/KR2011/000654 patent/WO2011096688A2/en active Application Filing
- 2011-01-31 JP JP2012551913A patent/JP5694382B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879558B1 (en) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | Skin protection and improvement agent containing dibenzo 함유 paradioxin derivative as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
WO2011096688A3 (en) | 2012-01-05 |
JP5694382B2 (en) | 2015-04-01 |
KR20110090174A (en) | 2011-08-10 |
WO2011096688A2 (en) | 2011-08-11 |
JP2013518875A (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101201524B1 (en) | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives | |
KR101402417B1 (en) | Anti-fungal composition comprising Filobasidium inhibiting substances derived from natural products | |
KR102475897B1 (en) | Mask cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
JP2005213178A (en) | TNF-alpha PRODUCTION INHIBITOR, ESTROGENIC AGENT AND EXTERNAL PREPARATION FOR SKIN | |
KR20110085371A (en) | Cosmetic composition for improving the scalp state containing natural plant extracts | |
KR101464914B1 (en) | Composition for curing acne with skin barrier reinforcement and skin cell regeneration and method for manufacturing the same | |
KR20170133560A (en) | A cosmetic composition for scalp and hair improvement comprising multiple extract of combined medicinal herbs | |
KR101220508B1 (en) | Composition for improvement of health of scalp and hair comprising dibenzo-p-dioxin derivatives | |
KR101530415B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract of Platycarya strobilacea | |
JP4906179B2 (en) | Topical skin preparation | |
KR20220153866A (en) | External Composition Comprising Plant Extracellular vesicle of Rose for Improving Skin | |
KR101252554B1 (en) | Composition capable of inhibiting sebum secretion | |
KR100777542B1 (en) | Anti-dandruff hair cosmetic composition | |
KR20230172226A (en) | External Composition Comprising Lavandula Angustifolia Leaf Cell Extract for improvement of skin barrier by external stimulus and soothing effect of skin(redness) by external stimulus | |
KR20210009178A (en) | Compositions containing Gastrodia extracts | |
KR101396275B1 (en) | The extract from Dalbergia odorifera T. having skin whitening activity | |
KR100682979B1 (en) | Composition for prophylactic treatment against antimicrobial infection and anti-inflammatory action and athlete's foot therapeutic agent obtained using the composition | |
WO2019009663A1 (en) | Composition for preventing and ameliorating athlete's foot | |
JPH03112912A (en) | Cosmetic composition | |
KR102297607B1 (en) | Composition for improved atopy skin and skin moisturizing comprising asiatic tearthumb | |
KR101177500B1 (en) | Hair growth stimulating composition | |
KR102676799B1 (en) | External Composition Comprising Natural Complex Extract for Improving Skin | |
KR20210068936A (en) | Composition for improved atopy skin and skin moisturizing comprising natural extract | |
KR102428010B1 (en) | Skin external composition | |
Amornopparattanakul et al. | Development of Oral Cleansing Products Containing Green Tea and Centella asiatica Extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100203 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111127 Patent event code: PE09021S01D |
|
A107 | Divisional application of patent | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20120327 Patent event code: PA01071R01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120824 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20121108 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20121109 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20151109 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20151109 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161108 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20161108 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171208 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20171208 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181108 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20181108 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20191101 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20201109 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20211108 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20221108 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20231108 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20250108 Start annual number: 13 End annual number: 13 |